Complex immunogenicity assessment in caplacizumab-treated patients with immune-mediated thrombotic thrombocytopenic purpura who have received plasma exchange by Brendy Van Butsel, Maria Laura Sargentini-Maier, Ana Paula Marques, Yana Vandenbossche, Gabriela Marcheva, Sriya Gunawardena, Samuel Pine

Get full text

A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAPLACIZUMAB WITHOUT FIRST-LINE THERAPEUTIC PLASMA EXCHANGE IN ADULTS WITH IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPUR... by Sriya GUNAWARDENA, MD, Angela HU, MD, Laurel A. MENAPACE, MD, Hikaru OKADA, MD, PhD, Beverly ACCOMANDO, MS, Julie LIN, MD

Get full text

THE ROLE OF ADAMTS13 ACTIVITY LEVELS ON DISEASE EXACERBATION OR RELAPSE IN PATIENTS WITH IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA: POST HOC ANALYSIS OF THE PHASE 3 HERCU... by Johanna KREMER HOVINGA, Javier DE LA RUBIA, Katerina PAVENSKI, Ara METJIAN, Paul KNÖBL, Flora PEYVANDI, Spero CATALAND, Paul COPPO, Umer KHAN, Laurel A. MENAPACE, Ana PAULA MARQUES, Sriya GUNAWARDENA, Marie SCULLY

Get full text

LONG-TERM OUTCOMES OF PATIENTS TREATED WITH CAPLACIZUMAB FOR IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP): THE POST-HERCULES STUDY by Özgür Pektaş, Marie Scully, Javier de la Rubia, Katerina Pavenski, Ara Metjian, Paul Knöbl, Flora Peyvandi, Spero Cataland, Paul Coppo, Johanna A. Kremer Hovinga, Jessica Minkue Mi Edou, Rui de Passos Sousa, Sriya Gunawardena, Julie Lin

Get full text